SK

Subhashchandra Khetaram Choudhary

Active Director Director DIN 05173670
DIN 05173670 First appointment Jun 1995 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jun 1995
Shareholding value β€’β€’β€’β€’ Premium profile

About Subhashchandra Khetaram Choudhary

Data last updated:

Subhashchandra Khetaram Choudhary is a Director at Novus Pharmaceuticals Limited (since 1995). The company operates in Pharma.

DIN 05173670
Primary Designation Director
Industry Pharma
First Appointment 20 Jun 1995
Oldest Company Age 31 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Novus Pharmaceuticals Limited U24230MH1995PLC089743
Director20 Jun 19951995Active

Board colleagues of Subhashchandra Khetaram Choudhary

Directorship timeline

Open interactive timeline →
Novus Pharmaceuticals Limited
Premium access

Shareholding and investment profile for Subhashchandra Khetaram Choudhary

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Subhashchandra Khetaram Choudhary

Subhashchandra Khetaram Choudhary currently holds 1 directorship: Novus Pharmaceuticals Limited (Director, since 20 Jun 1995).

Subhashchandra Khetaram Choudhary was first appointed on 20 Jun 1995 as Director at Novus Pharmaceuticals Limited.

The current boards of Subhashchandra Khetaram Choudhary's companies include Omprakash Sitaram Saraf (Novus Pharmaceuticals Limited), Pramod Sitaram Saraf (Novus Pharmaceuticals Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available